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Abstract (250 words; limit: 250 words) 36 
 37 
Certain major histocompatibility complex class-I (MHC-I) alleles are associated with 38 
spontaneous control of viral replication in human immunodeficiency virus (HIV)-infected people 39 
and simian immunodeficiency virus (SIV)-infected rhesus macaques (RMs). These cases of 40 
“elite” control of HIV/SIV replication are often immune-mediated, thereby providing a framework 41 
for studying anti-lentiviral immunity. Here we examined how vaccination impacts SIV replication 42 
in RMs expressing the MHC-I allele Mamu-B*17. Approximately 21% of Mamu-B*17+ and 50% 43 
of Mamu-B*08+ RMs control chronic phase viremia after SIVmac239 infection. Because CD8+ 44 
T-cells targeting Mamu-B*08-restricted SIV epitopes have been implicated in virologic 45 
suppression in Mamu-B*08+ RMs, we investigated whether this might also be true for Mamu-46 
B*17+ RMs. Two groups of Mamu-B*17+ RMs were vaccinated with genes encoding Mamu-47 
B*17-restricted epitopes in Vif and Nef. These genes were delivered by themselves (Group 1) or 48 
together with env (Group 2). Group 3 included MHC-I-matched RMs and served as the control 49 
group. Surprisingly, the Group 1 vaccine regimen had little effect on viral replication compared 50 
to Group 3, suggesting that, unlike Mamu-B*08+ RMs, pre-existing SIV-specific CD8+ T-cells 51 
alone do not facilitate long term virologic suppression in Mamu-B*17+ RMs. Remarkably, 52 
however, 5/8 Group 2 vaccinees controlled viremia to <15 viral RNA copies/mL soon after 53 
infection. No serological neutralizing activity against SIVmac239 was detected in Group 2, 54 
although vaccine-elicited gp140-binding antibodies correlated inversely with nadir viral loads. 55 
Collectively, these data shed new light into the unique mechanism of elite control in Mamu-56 
B*17+ RMs and implicate vaccine-induced, non-neutralizing anti-Env antibodies in the 57 
containment of immunodeficiency virus infection.  58 
59 
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 4 
Importance (150 words; limit: 150 words) 60 
 61 
A better understanding of the immune correlates of protection against HIV might facilitate 62 
the development of a prophylactic vaccine. Therefore, we investigated simian immunodeficiency 63 
virus (SIV) infection outcomes in rhesus macaques expressing the major histocompatibility 64 
complex class I allele Mamu-B*17. Approximately 21% of Mamu-B*17+ macaques 65 
spontaneously control chronic phase viremia after SIV infection, an effect that may involve 66 
CD8+ T-cells targeting Mamu-B*17-restricted SIV epitopes. We vaccinated Mamu-B*17+ 67 
macaques with genes encoding immunodominant epitopes in Vif and Nef alone (Group 1) or 68 
together with env (Group 2). Although neither vaccine regimen prevented SIV infection, 5/8 69 
Group 2 vaccinees controlled viremia to below detection limits shortly after infection. This 70 
outcome, which was not observed in Group 1, was associated with vaccine-induced, non-71 
neutralizing Env-binding antibodies. Together, these findings suggest a limited contribution of 72 
Vif- and Nef-specific CD8+ T-cells for virologic control in Mamu-B*17+ macaques and implicate 73 
anti-Env antibodies in containment of SIV infection.  74 
 75 
 76 
 77 
  78 
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 5 
Introduction 79 
 80 
 Despite improvements in prevention strategies and antiretroviral therapy (ART) coverage, 81 
thousands of new human immunodeficiency virus (HIV) infections are still occurring every day, 82 
highlighting the need for an effective HIV vaccine (1). Eliciting robust protection against HIV 83 
infection has not been straightforward, as seen by the failure of most HIV vaccines tested in 84 
humans to date (2–6). Although the RV144 trial remains the only report of vaccine-mediated 85 
reduction in HIV infection rates (7), the observed results were modest, short-lived, and continue 86 
to be contested (8, 9). The unsatisfactory performance of mainstream HIV vaccine regimens 87 
underscores the need to better understand the nature of effective anti-lentiviral immune 88 
responses.  89 
 Elite controllers (ECs) are a small fraction of HIV-infected individuals who spontaneously 90 
control chronic phase viremia in the absence of ART (10). Certain major histocompatibility 91 
complex class I (MHC-I) alleles, such as HLA-B*27 and HLA-B*57, are associated with elite 92 
control of HIV-1 infection (11), implying an immunological basis for this phenotype. Indeed, 93 
CD8+ T-cells targeting viral epitopes restricted by “protective” MHC-I molecules and natural 94 
killer (NK) cells are widely thought to be important mediators of antiviral activity in ECs (12, 13). 95 
The study of ECs thus provides a useful framework to investigate the basis for immune 96 
containment of lentivirus replication. Similar to human ECs, certain rhesus macaque (RM) MHC-97 
I alleles are also associated with elite control of SIV infection. Indeed, approximately 21% of 98 
unvaccinated RMs expressing Mamu-B*17 control chronic phase viral replication after infection 99 
with SIVmac239 (14). The incidence of elite control in Mamu-B*08+ RMs is higher, reaching 100 
50% of infected animals (15). Curiously, the peptide binding motifs of the Mamu-B*08 and 101 
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 6 
Mamu-B*17 molecules resemble those of HLA-B*27 and HLA-B*57, respectively (16, 17). This 102 
similarity is not explained by sequence homology between the human and RM MHC-I alleles, 103 
thereby implicating the presented peptide as an important determinant of elite control.  104 
The immunodominant SIV epitopes restricted by Mamu-B*08 and Mamu-B*17 share a 105 
common feature, that is, their location in the accessory proteins Vif and Nef (18–20). While 106 
CD8+ T-cell responses targeting these Vif and Nef epitopes are crucial for virologic control in 107 
Mamu-B*08+ RMs (21), it is not clear to what extent Vif- and Nef-specific CD8+ T-cells 108 
contribute to the EC phenotype of Mamu-B*17+ RMs. We set out to clarify this issue by 109 
conducting an SIV vaccine trial in Mamu-B*17+ RMs. We hypothesized that vaccine-induced 110 
CD8+ T-cells targeting the immunodominant Mamu-B*17-restricted Vif HW8 (amino acids 66-111 
73) and Nef IW9 (amino acids 165-173) epitopes would increase the incidence of elite control in 112 
Mamu-B*17+ RMs following infection with SIVmac239. Because vaccine-elicited anti-Env 113 
antibodies (Abs) have been linked to delayed acquisition of immunodeficiency virus infection 114 
following repeated mucosal challenges (22–24), we also evaluated whether these humoral 115 
responses would increase the protective efficacy of Vif HW8- and Nef IW9-specific CD8+ T-cells 116 
induced by vaccination. To this end, we used a heterologous prime/boost/boost/boost/boost 117 
(PBBBB) immunization regimen to vaccinate two groups of Mamu-B*17+ RMs with genes 118 
encoding the Vif HW8 and Nef IW9 epitopes. These epitopes were delivered by themselves 119 
(Group 1) or together with env (Group 2). As a result, vaccinees in both groups mounted Vif and 120 
Nef-specific CD8+ T-cells but only the ones in Group 2 developed Env-specific Abs. We 121 
assessed the efficacy of both regimens by repeatedly challenging vaccinees along with sham-122 
vaccinated MHC-I-matched control RMs (Group 3) intrarectally with a marginal dose of 123 
SIVmac239. The challenge outcomes varied greatly between Groups 1 and 2, thereby revealing 124 
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 7 
important aspects of immune containment of lentivirus replication. Here we discuss the 125 
relevance of these findings for HIV vaccine development and for understanding the basis of elite 126 
control of SIV replication in Mamu-B*17+ RMs.  127 
 128 
Results 129 
 130 
 Twenty-three RMs expressing the MHC-I allele Mamu-B*17 were used in this study. 131 
These animals were divided among three groups, depending on which immunogens they 132 
received. RMs in Group 1 (n = 7) were vaccinated with genes encoding the immunodominant Vif 133 
HW8 and Nef IW9 epitopes, whereas those in Group 2 (n = 8) received the same inserts with 134 
the addition of env (Fig. 1). The SIV sequences were delivered by a recombinant (r) yellow fever 135 
virus 17D (rYF17D) prime followed by three boosts with rDNA plasmids delivered by 136 
intramuscular electroporation (EP rDNA). Subsequently, vaccinees in Groups 1 and 2 were 137 
boosted once with each of the following viral vectors: adenovirus type-5 (rAd5), vesicular 138 
stomatitis virus (rVSV), and rhesus monkey rhadinovirus (rRRV) (Fig. 1). We used this PBBBB 139 
vaccine regimen because recurrent antigen stimulation is thought to facilitate the induction of 140 
effective cellular and humoral immune responses against lentiviruses (25, 26). It should be 141 
noted that some of the vaccine vectors employed in this study encoded segments of vif and nef, 142 
or full-length vif and nef fused with other genes, such as tat and rev (see Materials and 143 
Methods). As a result, RMs in Groups 1 and 2 also developed cellular immune responses 144 
against Tat and Rev. Additionally, some of the vaccine-encoded immunogens also included the 145 
subdominant Mamu-B*17-restricted epitopes Nef MW9 (amino acids 195-203) and, in the case 146 
of Group 2, Env FW9 (amino acids 830-838). Finally, eight Mamu-B17+ RMs were immunized 147 
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 8 
with vectors encoding irrelevant antigens or lacking any inserts (“empty” vectors) and served as 148 
the controls for this experiment (Group 3; Fig. 1).  149 
 We monitored vaccine-induced CD8+ T-cell responses against Mamu-B*17-restricted 150 
epitopes by staining PBMC with fluorochrome-labeled MHC-I tetramers. This analysis revealed 151 
that the PBBBB regimen generated high-frequency SIV-specific CD8+ T-cell responses in the 152 
majority of the Group 1 and Group 2 vaccinees (Fig. 2). Consistent with the immunodominance 153 
of Vif HW8 and Nef IW9 during SIV infection (20), vaccine-elicited CD8+ T-cells in Groups 1 and 154 
2 were primarily directed against these two epitopes (Fig. 2A-D). Curiously, while Nef MW9-155 
specific CD8+ T-cells were undetectable or at borderline levels in all Group 2 vaccinees, low to 156 
modest frequencies of these responses were observed in several RMs in Group 1 (Fig. 2E&F). 157 
A few macaques in Group 2 developed Env FW9-specific CD8+ T-cells but these responses 158 
remained scarce throughout the vaccine phase (Fig. 2G).  159 
 We also determined the magnitude of vaccine-induced SIV-specific T-cell responses in 160 
Groups 1 and 2 by performing intracellular cytokine staining (ICS) in PBMC at the time of the 161 
first IR SIV challenge (Fig. 3). In accordance with the MHC-I tetramer analysis, vaccine-induced 162 
CD8+ T-cell responses in Groups 1 and 2 were mainly directed against Vif and Nef, although a 163 
few animals in each group developed responses against Rev, Tat, and Env (Group 2 only) as 164 
well (Fig. 3A&B). Vaccine-elicited CD4+ T-cell responses in Group 2 were detected at higher 165 
frequencies than those in Group 1 and focused primarily on Env (Fig. 3A-C). There was no 166 
significant difference in the total magnitude of vaccine-elicited SIV-specific CD8+ or CD4+ T-cell 167 
responses between Groups 1 and 2 (Fig. 3C).   168 
 Vaccine-elicited Env-specific humoral responses in Group 2 were also evaluated at 169 
multiple time points during the vaccine phase. A longitudinal analysis of gp140-binding Abs 170 
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 9 
showed substantial increases in these responses after the EP rDNA and rAd5 vaccinations (Fig. 171 
4A). Subsequent boosting with rVSV, but not with rRRV, resulted in a modest rise in these 172 
responses (Fig. 4A). We also quantified vaccine-elicited gp140-binding Abs on the day of the 1st 173 
SIV challenge (Fig. 4B). The median endpoint titer of gp140-binding Abs in Group 2 was 4,800 174 
(Fig. 4B)–a value that was twice as high as that induced by an EP rDNA/rAd5/rVSV/rRRV 175 
vaccine regimen recently tested by our group (27). However, these responses were still about 176 
100-fold lower than those generated by live-attenuated SIV vaccination (Fig. 4B). Low levels of 177 
NK cell-mediated, Ab-dependent cellular cytotoxicity (ADCC) against SIVmac239-infected cells 178 
were also detected in plasma from r08047 and r09062 collected on the day of the 1st SIV 179 
challenge, but ADCC activity was either absent or at borderline levels in the other animals (Fig. 180 
4C). No neutralizing antibodies (nAbs) against SIVmac239 were detected on the day of the 1st 181 
SIV challenge or after SIV infection (Table 1).  182 
 To assess vaccine efficacy, all RMs in Groups 1-3 were subjected to repeated IR 183 
challenges with a marginal dose of SIVmac239 every two weeks, starting at study week 101 184 
(Fig. 1). The challenge inoculum consisted of 200 50% tissue culture infective doses (TCID50) of 185 
an in vivo-titrated SIVmac239 stock. As a reference, the challenge dose employed here typically 186 
infects 80% of SIV naïve RMs after six IR exposures. RMs in Groups 1-3 became infected at 187 
similar rates (Fig. 5), indicating that vaccine-induced immune responses did not block 188 
acquisition of SIVmac239 infection.  189 
Contrary to our expectations based on control of SIVmac239 replication in Mamu-B*08+ 190 
RMs vaccinated with Vif and Nef (21), vaccine-induced CD8+ T-cell responses targeting the 191 
immunodominant Mamu-B*17-restricted Vif HW8 and Nef IW9 epitopes resulted only in a 192 
modicum of virologic control in Group 1 (Fig. 6A). Although two vaccinees (r09001 and r08034) 193 
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 10 
fared well in the chronic phase, none of the Group 1 RMs suppressed viremia to <15 viral 194 
(v)RNA copies/mL and the latter RM lost control of viral replication after week 32 PI (Fig. 6A). 195 
The number of infected monkeys with chronic phase VLs below 1,000 vRNA copies/mL, even if 196 
transiently as in the case of r08034, was similar to that in Group 3, where r10018 developed a 197 
viral setpoint of approximately 1,000 vRNA copies/mL while r09083 controlled viral replication to 198 
<15 vRNA copies/mL at week 20 PI (Fig. 6A&C). 199 
 Surprisingly, however, Group 2 exhibited an entirely unexpected outcome after infection. 200 
Despite experiencing peak VLs in excess of 8.5×105 vRNA copies/mL of plasma, five Group 2 201 
vaccinees (r05007, r08046, r08062, r08047, and r09062) controlled viral replication to <15 202 
vRNA copies/mL by weeks 4-8 post infection (PI) (Fig. 6B). This corresponded to an average 203 
reduction in VLs of 5.3 logs, which was effected within only 2-6 weeks after peak viremia. Four 204 
of the five Group 2 vaccinees that showed early viral suppression maintained control of viral 205 
replication throughout the chronic phase. RM r08047 was the exception, as its VLs 206 
progressively increased after week 20 PI (Fig. 6B). Of note, after decreasing viremia to <15 207 
vRNA copies/mL, the Group 2 controllers experienced occasional VLs blips in the ensuing 208 
weeks, similar to those reported by Hansen et al. (28) and Winstone et al. (29). RM r08062 209 
began to deviate from this pattern at week 16 PI, after which viremia became persistent, albeit 210 
at low levels (140 vRNA copies/mL at week 75 PI; Fig. 6B).  211 
 We compared VLs among Groups 1-3 and made several observations about post-212 
infection viral control in these groups. First, five Group 2 vaccinees had VLs that were either at 213 
or below the limit of detection (15 vRNA copies/mL) on day 6 PI (Fig. 7A), implying early control 214 
of viral replication. By comparison, only one vaccinee in Group 1 (r09090) and two monkeys in 215 
Group 3 (r08051 and r09038) had VLs below 15 vRNA copies/mL at this time point (Fig. 7A). 216 
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 11 
These differences were not, however, statistically significant (Fig. 7A). Second, peak VLs were 217 
significantly lower in Groups 1 and 2 than in Group 3, although these reductions were modest 218 
(Fig. 7B). Curiously, the two RMs (r03139 and r09090) with the lowest peak VLs were in Group 219 
1 (Fig. 7B). Third, although setpoint VLs were not significantly decreased in either vaccinated 220 
group, Group 2 (but not Group 1) exhibited a significant reduction in nadir VLs, consistent with 221 
stringent control of post-acute viremia being the most distinctive feature of Group 2 (Fig. 7C&D). 222 
Fourth, it took a median of 1.46 weeks for the Group 1 macaques to experience peak viremia 223 
after SIV infection, compared to medians of 2 and 2.5 weeks in Groups 2 and 3, respectively 224 
(Fig. 7E). This difference between Group 1 and the other groups was statistically significant, 225 
although it is not clear why viral replication peaked earlier in the Group 1 vaccinees. There was 226 
no statistically significant difference in the time-to-peak VLs between Groups 2 and 3, despite a 227 
few outliers in the latter group (Fig. 7E). 228 
 It is important to emphasize that the level of control of chronic phase SIVmac239 229 
replication manifested by the five controller Group 2 vaccinees is exceedingly rare. In fact, of the 230 
197 RMs that have been rectally infected with SIVmac239 as part of eight previous and ongoing 231 
SIV vaccine trials conducted by our group, none exhibited the 5.3-log reduction in VLs within 2-6 232 
weeks of peak viremia observed in the five Group 2 controllers (Fig. 8). Of note, this cumulative 233 
past experience also included RMs that expressed MHC-I alleles associated with elite control of 234 
SIV infection (Fig. 8D-H). These animals were vaccinated with various heterologous prime boost 235 
regimens encoding vif, nef, rev, and tat (Fig. 8D), nef only (Fig. 8E), rev, tat, and nef (Fig. 8F), 236 
and vif only (Fig. 8G). The Mamu-B*08+ vaccinees in Fig. 8H were vaccinated with vif and nef 237 
minigenes containing Mamu-B*08-restricted epitopes or with minigenes of other regions of the 238 
SIV proteome that lack CD8+ T-cell determinants restricted by Mamu-B*08. As expected, a 239 
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fraction of these SIVmac239-infected RMs became ECs but, even in these cases, viremia was 240 
rarely reduced to <15 vRNA copies/mL by weeks 4-8 PI (Fig. 8D-H). These different kinetics of 241 
virologic control after SIVmac239 infection underscore the uniqueness of the five Group 2 242 
controllers.  243 
 We have recently reported an extraordinary case of control of SIVmac239 infection in a 244 
vaccinated RM (Fig. 8E and (30)). However, the virus replicating in that animal contained a 245 
deletion in nef as early as week 2 PI, which likely compromised its replicative fitness. Given this 246 
precedent, we explored the possibility that the Group 2 controllers harbored attenuated viruses, 247 
even though we have previously shown that the SIVmac239 challenge stock employed here is 248 
made almost entirely of wild-type genomes (30). We conducted this analysis in acute phase 249 
(weeks 2-4 PI) plasma from the four RM manifesting the earliest control of viral replication 250 
(r08046, r05007, r08062, and r08047) and found >99% homogeneity in nef sequences amplified 251 
at week 2 PI (Fig. 9). Viral sequence variation was more prevalent in the later time points, 252 
especially in r08062 and r08047 (Fig. 9C&D), but none of the nef sequences analyzed 253 
contained insertions or deletions (Fig. 9). Of note, both the Nef IW9 and Nef MW9 epitopes were 254 
essentially intact in these acute phase samples (Table 2). Thus, gross genetic defects in nef 255 
were not detected in the acute phase virus of 4/5 Group 2 controllers, corroborating the 256 
interpretation that the outstanding control of SIVmac239 replication manifested by these RMs 257 
was vaccine-mediated. 258 
We also analyzed env sequence evolution in the aforementioned acute phase samples 259 
and found no overlap in the diversity patterns detected in r08046, r05007, r08062, and r08047 260 
(Fig. 10). In spite of many low frequency mutations scattered throughout env in all four RMs, 261 
only a few variants were present at ≥10% frequencies (Fig. 10). RM r08046 exhibited a R751G 262 
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substitution at week 4 PI that was present in 81% of sequence reads (Fig. 10A). This 263 
polymorphism is frequently observed in virus isolated from SIVmac239-infected RMs and does 264 
not by itself significantly alter virus infectivity in vitro (31). One of the env changes in r08062 265 
resulted in a stop codon in gp120 (W225Stop) and comprised 40% of the circulating viral 266 
quasispecies at week 3 PI (Fig. 10C). However, viral variants harboring this stop codon were no 267 
longer detected in week 8 plasma from r08062 (Suppl. Fig. 1). This RM also exhibited a 268 
synonymous mutation in the Leu codon at position 656 (CTA->TTA) in 100% of sequence reads 269 
(Fig. 10C). The other mutations in r08062 and in r08047 modified amino acids at various 270 
positions in gp120 and gp41 (Fig. 10C&D). Variants of the Env FW9 epitope were detected at 271 
weeks 2-4 PI but these mutants never reached frequencies >6% (Table 2). A summary of amino 272 
acid substitutions in Env detected at ≥10% frequencies in these acute phase samples is shown 273 
in Fig. 11. Thus, a shared pattern of env sequence evolution did not explain the rapid post-acute 274 
phase virologic control manifested by 4/5 Group 2 controllers. 275 
 We then searched for vaccine-induced immune signatures that might explain the distinct 276 
virologic outcomes observed in Groups 1 and 2. Eight immunological variables determined 277 
either at the time of the first IR SIV challenge or at week 2.4 PI were selected for this analysis 278 
(Table 3). These variables were then compared with nadir VLs–the virologic marker most 279 
affected by vaccine-induced immune responses (Table 3). The only immunological predictor of 280 
virologic control that emerged from this analysis was the endpoint titer of vaccine-induced 281 
gp140-binding Abs in Group 2 at the time of the first SIV challenge, which inversely correlated 282 
with nadir VLs (Table 3; Fig. 12). This association was not, however, statistically significant after 283 
correcting for multiple comparisons. Collectively, these data suggest that in the context of potent 284 
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vaccine-elicited SIV-specific T-cell responses, increasing titers of gp140-binding Abs may result 285 
in substantial control of viral replication in Mamu-B*17+ RMs.    286 
 287 
Discussion  288 
 289 
Here we explored whether vaccinating Mamu-B*17+ RMs with inserts encoding Mamu-290 
B*17-restricted SIV epitopes would increase the frequency of elite control after SIVmac239 291 
infection, as is the case with vaccination of Mamu-B*08+ RMs with Mamu-B*08-restricted SIV 292 
epitopes (21). We also examined whether the addition of env to the vaccine regimen would 293 
confer protection from mucosal acquisition of the challenge virus, as has been reported 294 
previously (22–24). To our surprise, none of the vif and nef-vaccinated Group 1 animals 295 
controlled viral replication to <15 vRNA copies/mL of plasma, suggesting that the underlying 296 
mechanisms of elite control differ between Mamu-B*17+ and Mamu-B*08+ RMs. Even though 297 
the inclusion of env in the vaccine did not prevent acquisition of SIVmac239, we identified 298 
remarkable levels of virologic control in most of the Group 2 vaccinees. Indeed, 5/8 Group 2 299 
RMs (vaccinated with vif, nef, and env) suppressed viral replication to <15 vRNA copies/mL of 300 
plasma by 4-8 weeks PI. This virologic control did not correlate with vaccine-induced SIV-301 
specific T-cells or NK cell-mediated ADCC activity, nor did it depend on anti-SIVmac239 nAbs 302 
because serological neutralizing activity against SIVmac239 was not detected at the time of the 303 
1st SIV challenge or even shortly after infection. Vaccine-elicited gp140-binding Abs at the time 304 
of challenge were the only immune predictor of virologic control in Group 2.  305 
Approximately 50% of Mamu-B*08+ and 21% of Mamu-B*17+ SIV naïve RMs become 306 
ECs after SIVmac239 infection (14, 15, 20). Given the virulence of SIVmac239, elite control in 307 
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this context is defined as having a setpoint VL ≤1,000 vRNA copies/mL of plasma. Of note, 308 
expression of these alleles does not affect acute phase viremia after primary SIVmac239 309 
infection. Indeed, peak VLs are often indistinguishable between unvaccinated SIVmac239-310 
infected RMs expressing Mamu-B*08 or Mamu-B*17 and animals lacking these protective MHC-311 
I alleles (14, 15). Despite the predisposition of Mamu-B*17+ RMs to control SIV replication, the 312 
kinetics with which the five Group 2 controllers suppressed viremia in the present experiment 313 
was completely different from that seen in typical EC RMs. Our historical VL analysis of 314 
SIVmac239-infected animals shows that only a few RMs expressing MHC-I alleles associated 315 
with elite control of SIV infection controlled viremia to <15 vRNA copies/mL by week 20 PI (Fig. 316 
8D-H). Even in those few cases, it took on average 12 weeks for their plasma VLs to reach <15 317 
vRNA copies/mL. By comparison, the five Group 2 controllers in the present experiment 318 
controlled viremia to <15 vRNA copies/mL after an average of 6 weeks of infection. Vaccine-319 
induced Env-specific immune responses appeared to be required for this impressive outcome 320 
considering they were the only feature that distinguished Group 2 from Group 1. This conclusion 321 
is also supported by the inverse association between vaccine-elicited gp140-binding Ab titers 322 
and nadir VLs in Group 2. Nevertheless, assuming that Abs were involved in control, it is not 323 
clear how these vaccine-elicited gp140-specific Abs contributed to virologic control considering 324 
that they lacked neutralizing activity against SIVmac239 and their ability to recruit NK cell-325 
mediated ADCC activity against SIVmac239-infected cells did not predict post-infection VLs. 326 
One caveat to these analyses is the small number of animals in Group 2, which limited our 327 
ability to accurately identify immune correlates of virologic control. Additionally, given the wide 328 
range of non-neutralizing Ab effector functions reported for HIV-specific Abs (32), it is possible 329 
that antiviral activities other than NK-cell mediated ADCC might have explained the rapid control 330 
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of viral replication observed in some of the Group 2 vaccinees. Furthermore, the absence of a 331 
group of MHC-I-matched RMs vaccinated with env only also precludes any definitive 332 
conclusions regarding the role of vaccine-induced Env-specific immune responses in the 333 
challenge outcome. Such a group would have revealed whether or not vaccine-induced Env-334 
specific immune responses are sufficient for rapid post-acute phase control of viral replication in 335 
Mamu-B*17+ RMs and also to what extent vaccine-elicited T-cell responses against Vif and Nef 336 
contributed to virologic containment in the five Group 2 controllers. Additional experiments will 337 
be needed to elucidate these issues.  338 
The observation that the Group 1 vaccine regimen had little effect on viral replication 339 
compared to the control group suggests that, unlike Mamu-B*08+ RMs (21), pre-existing SIV-340 
specific CD8+ T-cells alone do not facilitate long term virologic suppression in Mamu-B*17+ 341 
RMs. These discordant outcomes imply a differential dependence on Vif- and Nef-specific CD8+ 342 
T-cells for elite control of SIV replication in Mamu-B*17+ and Mamu-B*08+ animals. In support 343 
of this notion, it is possible to predict which unvaccinated Mamu-B*08+ RMs will become ECs 344 
after SIVmac239 infection based on patterns of viral sequence evolution in Mamu-B*08-345 
restricted epitopes shortly after infection (33). In contrast, the emergence of CD8+ T-cell 346 
“escape” viral variants does not dictate the ability of certain Mamu-B*17+ animals to contain SIV 347 
viremia (20). In this regard, it is important to mention that other host genetic factors have also 348 
been associated with control of immunodeficiency virus replication (34). Thus, variability in such 349 
factors may explain the different SIV infection outcomes observed in vif- and nef-vaccinated 350 
Mamu-B*08+ versus Mamu-B*17+ RMs. Additional studies will be needed to elucidate the 351 
differences in elite control between Mamu-B*08+ and Mamu-B*17+ animals.  352 
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Importantly, the ability of gp140-binding Ab titers to predict vaccine-mediated control of 353 
SIVmac239 replication is not limited to Mamu-B*17+ RMs. We have recently reported that an 354 
EP rDNA/rAd5/rVSV/rRRV vaccine regimen encoding env, gag, vif, rev, tat, and nef resulted in 355 
substantial reductions in plasma VLs in SIVmac239-infected RMs lacking MHC-I alleles 356 
associated with elite control (27). Similar to the present study, vaccine-elicited Env-specific Abs 357 
lacked detectable neutralizing activity against SIVmac239 but their gp140-binding titers 358 
correlated with virologic control. Although vaccinees were not protected from SIV infection in 359 
either case, the fact that vaccine-induced gp140-binding Abs predicted control of viremia in 360 
these two independent settings is instructive for two reasons. First, the observation that high 361 
levels of vaccine-induced Env-specific Ab responses might improve control of viral replication in 362 
RMs regardless of their MHC-I genotype broadens the applicability of the present findings. 363 
Second, any immunological signature associated with containment of SIVmac239 infection 364 
warrants further investigation given the stringency of this molecular clone as a challenge virus 365 
(35). Indeed, most unvaccinated or drug-naïve SIVmac239-infected Indian RMs experience high 366 
peak (106-109 vRNA copies/mL) and setpoint (106 vRNA copies/mL) VLs and are euthanized 367 
due to AIDS-defining illnesses by two years after infection (36). Additionally, the SIVmac239 368 
Env glycoprotein is exceptionally difficult to neutralize (37–41), likely due to its closed 369 
conformation. Innumerable vaccine regimens have been evaluated using SIVmac239 370 
challenges, but relatively few have resulted in substantial reductions in viremia after infection 371 
(27, 29, 42–45) or prevented virus spread beyond the initial foci of infected cells (28, 46). 372 
However, except for live-attenuated SIV vaccines (47, 48), no active immunization strategy has 373 
consistently afforded sterilizing protection against challenge with SIVmac239. While certain 374 
features of the antiviral T-cell response elicited by live-attenuated SIV vaccines have been 375 
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identified as correlates of protection (48–51), vaccine efficacy in this case also relies heavily on 376 
Env-specific humoral immunity (52). The fact that only a fraction of SIVmac239∆nef-vaccinated 377 
RMs develops detectable anti-SIVmac239 nAb responses imply that Ab-mediated effector 378 
functions other than neutralization (e.g., ADCC) can also contribute to the efficacy of live-379 
attenuated SIV vaccines (52, 53). In this light, it is noteworthy that the titers of gp140-binding 380 
Abs elicited by SIVmac239∆nef vaccination exceeded those generated by our mixed modality 381 
vaccine regimens by approximately 100-fold (Fig. 4). Group 2 had greater titers of these 382 
responses than the aforementioned EP rDNA/rAd5/rVSV/rRRV group but this difference was not 383 
statistically significant. Although it is impossible at this point to establish a causal link between 384 
these anti-Env humoral responses and containment of viral replication, future studies should 385 
evaluate if the robust efficacy of live-attenuated SIV vaccination can be replicated by matching 386 
its titers of gp140-binding Abs.  387 
In conclusion, here we show that a rYF17D/EP rDNA/rAd5/rVSV/rRRV vaccine regimen 388 
encoding env and genes expressing Mamu-B*17-restricted CD8+ T-cell epitopes resulted in 389 
stringent control of viral replication in Mamu-B*17+ RMs shortly after SIVmac239 infection. We 390 
present evidence suggesting that vaccine-elicited Env-specific Abs devoid of detectable 391 
neutralizing activity against SIVmac239 were critical mediators of virologic control and that 392 
similar outcomes may be achieved in RMs that do not express protective MHC-I alleles. 393 
However, the exact mechanism by which these humoral responses exerted antiviral activity and 394 
to what extent cellular immune responses contributed to viral suppression remain undefined. 395 
These findings advance our understanding of vaccine-mediated control of lentivirus infection 396 
and establish a new benchmark for evaluating HIV vaccine candidates in the SIVmac239 397 
challenge model.  398 
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Materials and Methods 399 
 400 
Research Animals and Ethics Statement 401 
 402 
Twenty-four RMs expressing the Mamu-B*17 MHC-I allele were originally enrolled in this 403 
vaccine trial. Unfortunately, RM r04105 had to be euthanized due to recurrent diarrhea and 404 
weight loss, thus reducing the size of Group 1 to seven RMs. Because r04105 was euthanized 405 
at study week 39–before it was boosted with rAd5, this animal was not included in the 406 
immunological comparisons of vaccine-induced T-cell responses between Groups 1 and 2. 407 
The details regarding animal welfare described herein are either similar or identical to 408 
those published in one of our previous experiments. “The Indian RMs (Macaca mulatta) utilized 409 
in this study were housed at the Wisconsin National Primate Research Center (WNPRC). All 410 
animals were cared for in accordance with the guidelines of the Weatherall report and the 411 
principles described in the National Research Council’s Guide for the Care and Use of 412 
Laboratory Animals under a protocol approved by the University of Wisconsin Graduate School 413 
Animal Care and Use Committee” (animal welfare assurance no. A3368-01; protocol no. 414 
G00696) (54). “Furthermore, the RMs in this study were managed according to the animal 415 
husbandry program of the WNPRC, which aims at providing consistent and excellent care to 416 
nonhuman primates at the center. This program is employed by the Colony Management Unit 417 
and is based on the laws, regulations, and guidelines promulgated by the United States 418 
Department of Agriculture (e.g., the Animal Welfare Act and its regulations, and the Animal Care 419 
Policy Manual), Institute for Laboratory Animal Research (e.g., Guide for the Care and Use of 420 
Laboratory Animals, 8th edition), Public Health Service, National Research Council, Centers for 421 
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Disease Control, and the Association for Assessment and Accreditation of Laboratory Animal 422 
Care International. The nutritional plan utilized by the WNPRC is based on recommendations 423 
published by the National Research Council. Specifically, RMs were fed twice daily with 2050 424 
Teklad Global 20% Protein Primate Diet and food intake was closely monitored by Animal 425 
Research Technicians. This diet was also supplemented with a variety of fruits, vegetables, and 426 
other edible objects as part of the environmental enrichment program established by the 427 
Behavioral Management Unit. Paired/grouped animals exhibiting stereotypical and/or 428 
incompatible behaviors were reported to the Behavioral Management staff and managed 429 
accordingly. All primary enclosures (i.e., stationary cages, mobile racks, and pens) and animal 430 
rooms were cleaned daily with water and sanitized at least once every two weeks. Lights were 431 
on a 12:12 diurnal schedule. Vaccinations were performed under anesthesia (Ketamine 432 
administered at 5-12 mg/kg depending on the animal) and all efforts were made to minimize 433 
suffering. Euthanasia was performed at the end of the study or whenever an animal experienced 434 
conditions deemed distressful by one of the veterinarians at the WNPRC. All euthanasia were 435 
performed in accordance with the recommendations of the Panel on Euthanasia of the American 436 
Veterinary Medical Association and consisted of an IV overdose (greater than or equal to 50 437 
mg/kg or to effect) of sodium pentobarbital or equivalent, as approved by a clinical veterinarian, 438 
preceded by ketamine (at least 15 mg/kg body weight) given by the intramuscular (IM) route.” 439 
Additional animal information, including MHC-I alleles, age at the beginning of study, and sex, is 440 
shown in Table 4. 441 
 442 
Vaccinations 443 
 444 
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 The parental live-attenuated YF17DD vaccine strain and four rYF17D vectors expressing 445 
individual SIVmac239 inserts were used in this study. The SIVmac239 inserts encoded (1) Vif 446 
amino acids 1-110; (2) Nef amino acids 45-210; and (3) the amino terminus of gp41 (Env amino 447 
acids 526-690). In order to increase the stability of the latter rYF17D vector, the gp41 fusion 448 
peptide was inactivated and the Cys residues at positions 611 and 617 were mutated to Ala. 449 
The last SIVmac239 insert (4) consisted of a fusion of gp120 segments corresponding to amino 450 
acids 64-109, 209-315, and 343-502. The codon usage of the aforementioned SIVmac239 451 
inserts matched that of YF17D. RMs in Group 2 were vaccinated subcutaneously with 300,000 452 
plaque-forming units (PFU) of each of rYF17D vectors 1-4. These constructs were delivered in 453 
separate injections, each containing a final volume of 0.5 mLs. RMs in Group 1 were vaccinated 454 
in the same way, except that they received only vectors 1 and 2. RMs in Group 3 were sham-455 
vaccinated with the same dose of the parental YF17DD vaccine. The construction of some of 456 
the rYF17D vectors used here has been published elsewhere (55, 56).  457 
 A series of three EP rDNA vaccinations, given at 3-week intervals, started at study week 458 
12. Four pCMVkan plasmids encoding SIVmac239 minigenes were used in the EP rDNA 459 
vaccinations (57). These minigenes were identical to the ones delivered by the rYF17D vectors, 460 
except that the amino acid substitutions described above were reverted to wild-type and the SIV 461 
open reading frames were optimized for mammalian expression. RMs in Groups 1 and 2 were 462 
vaccinated with pCMVkan constructs encoding the aforementioned vif and nef minigenes. In 463 
addition to these constructs, RMs in Group 2 also received two pCMVkan plasmids encoding 464 
env minigenes described above. RMs in Group 3 were sham-vaccinated with “empty” pCMCkan 465 
plasmid. One milligram of each pCMVkan construct and 0.1 mg of the rhesus interleukin-12-466 
expressing AG157 plasmid were resuspended in 0.5 mL PBS and loaded into separate 467 
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injections. These DNA formulations were administered intramuscularly by the TriGrid in vivo 468 
electroporation system (Ichor Medical Systems, Inc., San Diego, CA). Muscles in the thighs and 469 
forearms were used for these vaccinations and these anatomical sites were rotated in 470 
subsequent immunizations so that each location did not receive vectors encoding the same SIV 471 
insert twice.   472 
 The rAd5 boost occurred at study week 54. RMs in Groups 1 and 2 were boosted with 473 
two rAd5 vectors produced by Viraquest, Inc., each encoding the same vif or nef minigenes 474 
described above that were also optimized for mammalian expression. RMs in Group 2 also 475 
received a rAd5 vector encoding the full-length SIVmac239 gp160 glycoprotein. RMs in Group 3 476 
were sham-vaccinated with “empty” Ad5 vectors lacking any inserts. The two latter Ad5 477 
constructs were produced by the International AIDS Vaccine Initiative. A dose of 1011 viral 478 
particles of each rAd5 vector was administered intramuscularly to sites in the forearms and 479 
thighs.   480 
 The rVSV boost occurred at study week 78. The rVSV vector was based on a modified 481 
attenuated virus strain developed by Profectus Biosciences (58). A rVSV vector encoding a 482 
fusion of the SIVmac239 Nef, Tat, and Vif proteins was used in RMs in both Groups 1 and 2. A 483 
separate rVSV vector encoding the SIVmac239 Env protein was administered to the Group 2 484 
vaccinees only. SIV Env was modified by replacing the cytoplasmic tail with the corresponding 485 
sequence from VSV G (59). RMs in Group 3 were sham-vaccinated with a rVSV construct 486 
encoding the malaria CSP antigen. All three rVSV vectors were provided by Profectus 487 
Biosciences. A dose of 107 PFU of each rVSV vector was administered intramuscularly to 488 
separate sites in the forearms and thighs.  489 
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 The rRRV boost occurred at study week 84. The Group 1 RMs were vaccinated with a 490 
mixture of three rRRV vectors, each expressing SIVmac239 vif, nef, and a fusion of the rev-tat-491 
nef genes. The Group 2 RMs received the same rRRV vectors with the addition of a rRRV 492 
construct expressing full-length env. The Group 3 RMs were sham-vaccinated with a rRRV 493 
vector encoding enhanced fluorescent green protein. One mL of PBS containing 7.1×107 494 
genome copies of each appropriate rRRV vector was administered via both intravenous and IR 495 
routes. Details about the generation of these rRRV vectors have been described previously (42).  496 
 497 
SIVmac239 challenges 498 
 499 
Seventeen weeks after the rRRV boost, RMs in Groups 1-3 were subjected to repeated 500 
IR inoculations of 200 TCID50 (4.8×10
5 vRNA copies) of the same SIVmac239 stock described in 501 
(30). These IR challenges occurred every two weeks. Plasma VLs were assessed six and ten 502 
days after each exposure. Once an animal experienced a positive VL at either one of these time 503 
points, it was no longer challenged. Only RMs that remained aviremic at both time points were 504 
re-challenged on day 14.  505 
 506 
SIV RNA viral load measurements 507 
 508 
The following description of plasma SIV RNA viral loads is identical to that published in 509 
one of our recent manuscripts (27). “VLs were measured using 0.5 mL of EDTA-anticoagulated 510 
rhesus macaque plasma based on a modification of a previously published (60). Total RNA was 511 
extracted from plasma samples using QIAgen DSP virus/pathogen Midi kits, on a 512 
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QIASymphonyXP laboratory automation instrument platform. Six replicate two step RT-PCR 513 
reactions were performed per sample using a random primed reverse transcription reaction, 514 
followed by 45 cycles of PCR using the following primers and probe: forward primer: SGAG21: 515 
5’-GTCTGCGTCAT(dP)TGGTGCA TTC-3’; reverse primer SGAG22: 5’-516 
CACTAG(dK)TGTCTCTGCACTAT(dP)TGTTTTG-3’; probe: PSGAG23: 5’-FAM-517 
CTTC(dP)TCAGT(dK)TGTTTCACTTTCTCTTCTGCG-BHQ1- 3’. The limit of reliable 518 
quantitation on an input volume of 0.5 mL of plasma was 15 vRNA copies/mL.” 519 
 520 
Quantification of Mamu-B*17 tetramer+ CD8+ T-cells in PBMC 521 
 522 
The following description is either identical or similar to that published in one of our recent 523 
manuscripts (27). Fluorochrome-labeled Mamu-B*17 tetramers produced at the NIH Tetramer 524 
Core Facility were used to quantify SIV-specific CD8+ T-cells in peripheral blood mononuclear 525 
cells (PBMC) according to a recently published protocol (61). Approximately 800,000 PBMC 526 
were incubated in R10 medium (RPMI 1640 medium supplemented with GlutaMax [Life 527 
Technologies], 10% FBS [VWR], and 1% antibiotic/antimycotic [VWR]) with titrated amounts of 528 
each tetramer at room temperature (RT) for 45 min. The cells were then stained with 529 
fluorochrome-labeled monoclonal antibodies (mAbs) directed against the surface molecules 530 
CD3 (clone SP34-2), CD8α (clone RPA-T8), CD14 (clone M5E2), CD16 (clone 3G8), and CD20 531 
(clone 2H7) for 25 min. This step also included an amine-reactive dye (ARD; Live/DEAD Fixable 532 
Aqua Dead Cell Stain; Life Technologies). The cells were then washed with Wash Buffer 533 
(Dulbecco's PBS with 0.1% bovine serum albumin and 0.45 g/L NaN3) and fixed with PBS 534 
containing 2% of paraformaldehyde (PFA) for 20 min at 4°C. The cells were washed one more 535 
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time before they were acquired in a Special-Order Product BD LSR II cytometer. The gating 536 
strategy used to analyze the data has been described elsewhere (61). Briefly, we used FlowJo 537 
9.6 to determine the percentages of live CD14- CD16- CD20- CD3+ CD8+ tetramer+ 538 
lymphocytes in PBMC. 539 
 540 
Intracellular cytokine staining (ICS) assays 541 
 542 
The following description is either identical or similar to that published in one of our recent 543 
manuscripts (27). Freshly isolated PBMC were cultured in R10 medium containing unlabeled co-544 
stimulatory mAbs against CD28 and CD49d and a phycoerythrin-conjugated mAb specific for 545 
CD107a. The tubes were kept in a 5.0% CO2 incubator for 9 hours (h) at 37 °C. One hour into 546 
the incubation period, Brefeldin A (Biolegend, Inc.) and GolgiStop (BD Biosciences) were added 547 
to all tubes in order to inhibit protein transport. The antigen stimuli consisted of three or five 548 
pools of SIVmac239 peptides (15mers overlapping by 11 aa) corresponding to (1) the entire Vif 549 
protein (amino acids 1-214), (2) the entire Nef protein (amino acids 1-263), (3) both Rev (amino 550 
acids 1-107) and Tat (amino acids 1-130) proteins, (4) Env gp120 (amino acids 1-531) and (5) 551 
Env gp41 (amino acids 516-879). The final concentration of each 15mer in the ICS tubes was 552 
1.0 μM. The same steps outlined above were used to stain the cells with mAbs against surface 553 
markers and subsequently fix them. The surface staining master mix included mAbs against 554 
CD4 (clone OKT4; Biolegend, Inc.) and CD8 (clone RPA-T8; Biolegend, Inc.), in addition to the 555 
same mAbs against CD14, CD16, and CD20 and the ARD reagent described above. For 10 556 
min, cells were permeabilized by homogenization in Perm Buffer (1X BD FACS lysing solution 2 557 
[Beckton Dickinson] and 0.05% Tween 20 [Sigma-Aldrich]), and then were washed with Wash 558 
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Buffer. Lastly, cells were incubated for 1 h in the dark at RT with mAbs against CD3 (clone 559 
SP34-2; BD Biosciences), IFN-γ (clone 4S. B3; Biolegend, Inc.), TNF-α (clone Mab11; BD 560 
Biosciences), and CD69 (clone FN50; Biolegend, Inc.). Once this incubation was completed, 561 
cells were washed and stored at 4 °C until acquisition. 562 
After gating on live CD14- CD16- CD20- CD3+ lymphocytes, we selected either CD4+ or 563 
CD8+ cells for subsequent analyses. Cells were considered positive for IFN-γ, TNF-α, or 564 
CD107a only if these molecules were co-expressed with CD69, a marker of recent activation. 565 
Leukocyte activation cocktail (LAC; BD Pharmingen)–stimulated cells stained with fluorochrome-566 
labeled control mAbs of the same isotypes as those against IFN-γ, TNF-α, and CD107a guided 567 
the identification of positive populations. Two criteria were used to determine a positive 568 
response. First, the frequency of events had to be ≥2-fold higher than their corresponding 569 
values in background-subtracted negative control tests. Second, the gates for each response 570 
had to contain ≥10 events. These calculations were performed with Microsoft Excel and results 571 
were presented as the percentage of responding CD4+ or CD8+ T-cells, that is, live CD14- 572 
CD16- CD20- CD3+ lymphocytes of either subset producing any combination of IFN-γ, TNF-α, 573 
or CD107a. 574 
 575 
Anti-Env antibody measurements by ELISA 576 
 577 
The following description is identical to that reported by our group in a recent publication 578 
(27). “Vaccine induced anti-Env responses were measured by ELISA. To begin, the ELISA plate 579 
was coated with 100 μL of purified SIVmac239 gp140 protein (Immune Technology Corp. #IT-580 
001-140p) at a concentration of 0.5 μg/mL and incubated overnight at RT. On the following day, 581 
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the plate was washed with 1× PBS-Tween20 and wells were blocked with 300 μL of 5% 582 
powdered milk in PBS for 1 hr at 37 °C. Subsequently, the plate was washed and 100 μL of 583 
diluted plasma samples were added to the corresponding wells. After a 1-hr incubation at RT, 584 
the plate was washed and 100 μL of a 1:2,000 dilution of Goat Anti-Monkey IgG-HRP antibody 585 
(Santa Cruz Biotechnology, sc-2458) were added to all wells for 1 hr at 37 °C. Finally, the plate 586 
was washed before being developed with 100 μL of 3,3',5,5'-Tetramethylbenzidine (EMD 587 
Millipore, 613544-100ML). After a short incubation, the reaction was stopped with TMB Stop 588 
Solution (Southern Biotech, 0412-01) and the plate was read (Biotek Synergy 2) at 450 nm. The 589 
endpoint antibody titers of vaccine-induced anti-Env antibody responses were measured in 590 
serum collected at the time of SIV challenge. These titers were determined as the greatest 591 
dilution at which the absorbance in experimental wells was at least two-fold higher than that 592 
measured in pooled pre-vaccination serum from all animals in the experiment.” 593 
 594 
Antibody dependent cellular cytotoxicity (ADCC) assay 595 
 596 
The following description is identical to that reported by our group in a recent publication 597 
(27). “The SIVmac239 and SHIVAD8-EO stocks used in ADCC assays were produced by 598 
transfection of infectious molecular clones into HEK293T cells using GenJet transfection 599 
reagent (SignaGen). Virus-containing supernatants were collected 48 and 72 h post-transfection 600 
and stored at –80 °C. The SHIVAD8-EO clone was provided by Dr. Malcom Martin (NIAID, 601 
Bethesda, MD). After heat inactivation for 30 min at 56 °C, RM plasma samples were tested for 602 
non-specific ADCC due to the presence of antibodies to human cellular antigens by co-603 
incubating uninfected CEM.NKR-CCR5-sLTR-Luc target cells (AIDS Research and Reference 604 
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Reagent Program, Division of AIDS, NIAID, NIH) with an NK cell line (KHYG-1 cells) expressing 605 
RM CD16 at a 10:1 effector-to-target ratio in the presence of serial dilutions of plasma (62). This 606 
NK cell line was developed in house, as described previously (59). Non-specific lysis was 607 
detected as a reduction in background luciferase activity (% RLU) for target cells incubated with 608 
NK cells in the presence compared to the absence of plasma. Plasma samples that directed 609 
ADCC against uninfected cells were depleted of anti-human antibodies by repeated cycles of 610 
incubation with CEM.NKR-CCR5-sLTR-Luc cells, followed by centrifugation and plasma 611 
transfer, until ADCC responses to uninfected cells were no longer detectable.” 612 
“To measure ADCC activity in plasma of vaccinated animals, CEM.NKR-CCR5-sLTR-Luc 613 
target cells were infected with SIVmac239 or SHIVAD8-EO (internal negative control) by 614 
spinoculation for 3 h at 1200 × g in the presence of 40 µg/mL polybrene (EMD Millipore). Four 615 
days post-infection, target cells were incubated with the NK cell line KHYG-1 at a 10:1 effector-616 
to-target ratio in the presence of serial plasma dilutions. Luciferase activity was measured after 617 
8 h using the britelite plus luciferase assay system (PerkinElmer). Triplicate wells were tested at 618 
each plasma dilution, and wells containing effector cells incubated with uninfected or infected 619 
target cells in the absence of plasma were used to determine background and maximal 620 
luciferase activity, respectively. ADCC responses were calculated from the dose-dependent loss 621 
of luciferase activity in the presence of plasma relative to background and maximal luciferase 622 
control wells.” 623 
  624 
Pseudovirus neutralization assays 625 
 626 
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The following description is nearly identical to that reported by our group in a recent 627 
publication (27). “Replication incompetent SIVmac239 pseudovirus was produced by co-628 
transfecting env plasmids with an env-deficient backbone plasmid (pSG3∆env) in HEK293T 629 
cells in a 1:2 ratio, using the X-tremeGENE 9 transfection reagent (Roche). Pseudovirus was 630 
harvested after 72 h by sterile-filtration (0.22 µm) of cell culture supernatants, and neutralization 631 
was tested by incubating pseudovirus and serum for 1 h at 37 °C before transferring them onto 632 
TZM-bl cells (AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH) 633 
as previously described (63). Neutralization was measured in duplicate wells within each 634 
experiment. Neutralization was tested starting at 1:20 serum dilutions followed by nine serial 3-635 
fold dilutions to ensure highest sensitivity and range of detection. Neutralization IC50 titers were 636 
calculated using the ‘One site – Fit logIC50’ regression in Graphpad Prism v7.0. We could not 637 
detect vaccine-induced nAb titers against SIVmac239 pseudovirus in any of the RMs in Group 2 638 
at the time of the first SIV challenge.” 639 
 640 
Amplicon-based sequencing of SIV nef and env 641 
 642 
Viral RNA was isolated from plasma using the QIAamp viral RNA mini kit (Qiagen) 643 
according to the manufacturer’s protocol and eluted in 60 μL of AVE buffer, aliquoted and stored 644 
at −80°C for future use. Viral RNA was reverse transcribed and amplified by using the 645 
SuperScript III One-Step RT-PCR system with High Fidelity Platinum Taq polymerase 646 
(Invitrogen). The 3' half of the genome was amplified in two amplicons SIVmac239-Amp3-5660-647 
F (5′-GGCATAGCCTCATAAAATATCTG-3′) and SIVmac239-Amp3-8487-R (5′-648 
ATTGCAGAACCTGCCGTTG-3′); SIVmac239-Amp4-7821-F (5′-649 
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CAGTCACCATTATGTCTGGATTG-3′) and SIVmac239-Amp4-10235-R (5′-650 
GAATACAGAGCGAAATGCAGTG3′).  All SIVmac239 primer positions are based on published 651 
SIVmac239 sequence present in GenBank (M33262). The RT-PCR conditions were as follows 652 
for 50°C for 30 min, 94 °C for 2 min; 40 cycles of 94 °C for 15 seconds (sec), 55 °C for 30 sec, 653 
and 68 °C for 3 min; and 68 °C for 5 min. 654 
Amplicons were visualized on a 1.0% agarose gel and purified using the Purelink quick 655 
gel extraction kit (Invitrogen). RT–PCR products were quantified using a Promega quantiflor-ST 656 
fluorometer (Promega) and analyzed for quality using an Agilent 2100 bioanalyzer with high 657 
sensitivity DNA chips. PCR amplicons were fragmented and barcoded using N exteraXT DNA 658 
Library Prep Kit, as per manufacturer’s protocol.  Samples were pooled and sequenced on an 659 
Illumina MiSeq platform, using a 2 x 250 bp V2 reagent kit. Paired-end reads obtained from 660 
Illumina MiSeq were then processed using our internal sequencing analysis pipeline which 661 
consists of removing PCR duplicate reads using FastUniq (64), quality trimming with 662 
trimmomatic (65) and de novo assembly using VICUNA (66) with finishing and annotation 663 
completed with V-FAT (https://www.broadinstitute.org/viral-genomics/v-fat).  Reads were then 664 
aligned to the consensus assembly using Mosaik v2.1.73 with V-Phaser v2.0 used to call intra-665 
host variants as described elsewhere (66–68). All raw sequence reads have been deposited to 666 
the NCBI Sequence Read Archive under the study accession number SRP016012 with the 667 
following experimental accession numbers SRX3797244 – SRX3797252.  668 
 669 
Statistics 670 
Peak VLs were determined as the highest VL measurement within the first 4 weeks after 671 
infection. Nadir VLs were considered as the lowest VL measurement between peak and week 8 672 
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PI. Setpoint VLs were calculated as the geometric mean of all VLs measured between week 8 673 
PI and the last chronic phase time point available. The Mann-Whitney U test was used to 674 
compare the total magnitude of vaccine-induced SIV-specific T-cell responses between Groups 675 
1 and 2. The Kaplan-Meier method and log-rank test were used to determine whether the Group 676 
1 or Group 2 vaccine regimens affected acquisition of SIV infection. For this analysis, the time-677 
to-productive infection was analyzed using the Kaplan-Meier method and the differences 678 
between Groups 1 and 3 and Groups 2 and 3 were evaluated using log-rank tests. The Mann-679 
Whitney U test was also used to determine the efficacy of each vaccine regimen in reducing 680 
viral replication. Viral loads at multiple time points were compared between each of Groups 1 681 
and 2 and the control Group 3. Lastly, the Spearman rank correlation was used to indicate 682 
immune correlates of protection. All significance tests were two-tailed.  683 
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Figure legends 1029 
 1030 
Figure 1. Experimental design. Twenty-three Mamu-B*17+ RMs were vaccinated with a 1031 
rYF17D/EP rDNA/rAd5/rVSV/rRRV regimen and divided among three groups depending on 1032 
which vaccine inserts they received. Animals in Group 1 (n = 7) were vaccinated with vif and nef 1033 
sequences. Animals in Group 2 (n = 8) were vaccinated with the same SIV inserts plus env. 1034 
RMs in Group 3 were sham-vaccinated with vectors lacking SIV genes or expressing irrelevant 1035 
inserts and served as the control group for this experiment. At study week 101, vaccine efficacy 1036 
was assessed by subjecting all animals to repeated intrarectal (IR) challenges with a marginal 1037 
dose of SIVmac239 (200 TCID50) every two weeks.  1038 
 1039 
Figure 2. Development of vaccine-induced CD8+ T-cell responses against Mamu-B*17-1040 
restricted SIV epitopes in Groups 1 and 2. Fluorochrome-labeled Mamu-B*17 tetramers 1041 
folded with peptides corresponding to SIV epitopes were used to track vaccine-elicited SIV-1042 
specific CD8+ T-cells in PBMC from RMs in Group 1 (A, C, E) and Group 2 (B, D, F, and G). 1043 
The percentages of live tetramer+ CD8+ T-cells specific for Vif HW8 (A and B), Nef IW9 (C and 1044 
D), Nef MW9 (E and F), and Env FW9 (G) are shown at multiple time points throughout the 1045 
vaccine phase. No Env FW9-specific CD8+ T-cell data are available for the Group 1 RMs 1046 
because those animals were not vaccinated with env. The times of each vaccination (black 1047 
vertical dotted lines) and the day of the first IR SIV challenge (red vertical solid line) are 1048 
indicated in each graph. RMs in Groups 1 and 2 are color-coded in blue and black, respectively.   1049 
 1050 
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Figure 3. Vaccine-induced SIV-specific CD4+ and CD8+ T-cell responses in Groups 1 and 1051 
2 at the time of the first SIV challenge. CD8+ and CD4+ T-cell responses were measured in 1052 
PBMC by ICS using pools of peptides (15mers overlapping by 11 amino acids) spanning the 1053 
appropriate SIVmac239 proteins. Peptides covering the Rev and Tat proteins were tested 1054 
together. The percentages of responding CD4+ or CD8+ T-cells displayed in all panels were 1055 
calculated by adding the frequencies of positive responses producing any combination of three 1056 
immunological functions (IFN-γ, TNF-α, and CD107a). The magnitude and specificity of vaccine-1057 
induced CD8+ (left panels) and CD4+ (right panels) T-cell responses are shown for Group 1 (A) 1058 
and Group 2 (B). C) Comparison of the total magnitude of vaccine-elicited SIV-specific CD8+ 1059 
(left panel) and CD4+ (right panel) between Groups 1 and 2. The Mann-Whitney U test was 1060 
used for these comparisons and no statistically significant difference was found. RMs in Groups 1061 
1 and 2 are color-coded in blue and black, respectively, and each symbol corresponds to one 1062 
vaccinee. Lines represent medians. NA, not applicable. NS, not significant.  1063 
 1064 
Figure 4. Vaccine-induced Env-specific humoral immune responses in Group 2. A) Env-1065 
binding antibodies (Abs) were measured by ELISA using plate-bound gp140 at multiple time 1066 
points during the vaccine phase. Straight 1:200 dilutions of plasma from each RM in Group 2 1067 
were used for this analysis. B) Log-transformed endpoint titers of vaccine-induced gp140-1068 
binding Abs in sera from the Group 2 vaccinees collected at the time of the first SIV challenge. 1069 
As a reference, these values were plotted alongside the endpoint titers of gp140-binding Abs in 1070 
four RM that had been infected with SIVmac239Δnef for 28 weeks as part of a previous 1071 
experiment (69). The endpoint titers of gp140-binding Abs in macaques vaccinated with an EP 1072 
rDNA/rAd5/rVSV/rRRV regimen encoding env, gag, vif, tat, rev, and nef are also shown (27). C) 1073 
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Ab-dependent cellular cytotoxicity (ADCC) activity was screened against SIVmac239-infected 1074 
target cells using plasma collected from the Group 2 vaccinees at the time of the first IR SIV 1075 
challenge (black lines). SHIVAD8-EO-infected target cells were used as internal controls (green 1076 
lines) for non-specific killing. The decrease in relative light units indicates the loss of virus-1077 
infected cells in the presence of an NK cell line during the duration of the assay. Dotted lines 1078 
denote 50% activity. Plasma from an SIV-infected RM (382-03) with a defined ADCC titer 1079 
against SIVmac239-infected cells was used as a positive control for these measurements.  1080 
 1081 
Figure 5. Kaplan-Meier rate of infection after repeated IR challenges with SIVmac239. 1082 
Macaques in Groups 1-3 were inoculated intrarectally with 200 TCID50 of SIVmac239 every 1083 
other week. The rate of SIV infection in Groups 1 and 2 was not significantly different than that 1084 
of Group 3. The P value for the Group 1 versus Group 3 comparison was 0.96. The P value for 1085 
the Group 2 versus Group 3 comparison was 0.28.  1086 
 1087 
Figure 6. Plasma viral RNA levels after SIVmac239 infection. Viral load (VL) traces for 1088 
individual animals in Group 1 (A), Group 2 (B), and Group 3 (C). VLs were log-transformed and 1089 
correspond to the number of vRNA copies/mL of plasma. The dotted lines in all the graphs are 1090 
for reference only and indicate a VL of 103 vRNA copies/mL. The dashed lines are also for 1091 
reference only and denote a VL of 106 vRNA copies/mL. The pink rectangle in each graph 1092 
frames the interval during which five Group 2 vaccinees controlled viremia to <15 vRNA 1093 
copies/mL. Groups 1, 2, and 3 are color-coded in blue, black, and red, respectively.  1094 
 1095 
Figure 7. SIV plasma viral load comparisons among Groups 1, 2, and 3. A) Plasma viral 1096 
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loads (VLs) measured on day 6 post infection (PI). B) Peak VLs. C) Nadir VLs. D) Setpoint VLs, 1097 
calculated as the geometric mean of VLs measured between week 8 PI and the last chronic 1098 
phase time point available. E) Time to peak viremia, determined as the week PI when each 1099 
animal experienced its peak VL. The dotted lines in graphs A-D are for reference only and 1100 
indicate a VL of 103 vRNA copies/mL. The dashed lines in graphs A-D are also for reference 1101 
only and denote a VL of 106 vRNA copies/mL. Lines represent medians and P-values were 1102 
calculated using the Mann-Whitney U test. Groups 1, 2, and 3 are color-coded in blue, black, 1103 
and red, respectively, and each symbol corresponds to one vaccinee.  1104 
 1105 
Figure 8. Viral loads in the five Group 2 controllers compared to those in RMs historically 1106 
infected with SIVmac239. The outcome of SIVmac239 infection in the five Group 2 vaccinees 1107 
that manifested early control of viral replication was compared to those of 197 RMs that were 1108 
rectally infected with SIVmac239 as part of eight SIV vaccine trials conducted by our group. The 1109 
historical viral loads (VLs) for each independent SIV vaccine trial are plotted in panels A-H and 1110 
include both vaccinated (gray lines) and control (salmon lines) RMs. VLs from RMs that 1111 
expressed MHC-I alleles associated with elite control of SIV infection (i.e., Mamu-B*08 and 1112 
Mamu-B*17) are shown in dashed lines. VLs from RMs that did not express these protective 1113 
MHC-I alleles are shown in solid lines. To better visualize the early control of viral replication 1114 
manifested by the five Group 2 vaccinees, their VLs (black lines) were also plotted in each 1115 
panel. Additionally, only the first 20 weeks of SIV infection are shown in each graph. A) In trial 1116 
#1, twenty-four RMs were vaccinated with env, gag, vif, rev, tat, and nef delivered by either 1117 
rRRV alone or rRRV followed by two boosts with rAd5 and rVSV. Eight RMs served as the 1118 
controls for the challenge phase (Martins et al., unpublished data). B) The details of this 1119 
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experiment were published recently (27). Briefly, thirty-two RMs were vaccinated with an EP 1120 
rDNA/rAd5/rVSV/rRRV regimen encoding four different sets of SIV inserts. Eight RMs served as 1121 
the controls for this experiment. One vaccinee did not get infected, so VL traces for 39 RMs are 1122 
shown in the graph. C) The details of this experiment were published recently (70). Briefly, four 1123 
different mixed modality vaccine regimens were used to deliver minigenes of SIV gag, vif, and 1124 
nef to 32 RMs. Eight RMs served as the controls for this experiment. D) Ten Mamu-B*08+ RMs 1125 
were vaccinated with a rAd5/rVSV/rRRV regimen encoding vif, rev, tat, and nef and six MHC-I-1126 
matched RMs served as the controls for the challenge phase (Martins et al., unpublished data). 1127 
Three vaccinees did not acquire SIV infection in this experiment so VL traces for 13 RMs are 1128 
shown in the graph. E) The details of this experiment were published recently (71). Briefly, 1129 
sixteen Mamu-B*08+ RMs were vaccinated with an EP rDNA/rYF17D/rAd5 regimen encoding 1130 
nef and two MHC-I-matched macaques served as the controls for the challenge phase. F) The 1131 
details of this experiment were published recently (30). Four RMs, two of which were Mamu-1132 
B*08+, were vaccinated with an EP rDNA/rYF17D/rRRV regimen encoding either gag or nef. 1133 
For unknown reasons, the animal highlighted in pink harbored a nef-deleted SIV variant as early 1134 
as week 2 PI. The replicative fitness cost imposed by this nef deletion likely underlies the 1135 
stringent control of viral replication manifested by this animal. G) Twenty RMs were vaccinated 1136 
with an EP rDNA/recombinant vaccinia/rVSV/rAd5/rRRV regimen encoding vif only. Twenty 1137 
MHC-I-matched RMs served as the controls for the challenge phase. Eight vaccinees and nine 1138 
control RMs expressed either Mamu-B*08 or Mamu-B*17 (Martins et al., unpublished data). One 1139 
vaccinee did not acquire SIV infection so VL traces for 39 RMs are shown in the graph. H) The 1140 
details of this experiment were published elsewhere (21). Briefly, sixteen Mamu-B*08+ RMs 1141 
were vaccinated with a rYF17D/rAd5 regimen encoding either vif and nef minigenes containing 1142 
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Mamu-B*08-restricted epitopes or regions of the SIV proteome lacking epitopes restricted by 1143 
Mamu-B*08. Four MHC-I-matched RMs served as the controls for the challenge phase. 1144 
 1145 
Figure 9. nef sequence diversity in acute phase plasma from four Group 2 controllers. 1146 
Heat maps illustrating the levels of sequence diversity at each codon in the nef open reading 1147 
frame. The range of amino acids covered by each row is indicated on the right-hand side of the 1148 
figure and should be used only as a reference because both synonymous and non-synonymous 1149 
mutations are considered in these heat maps. The codon corresponding to the first amino acid 1150 
in Nef is located in the top left corner of each grid. Each row spans 17 amino acids of the Nef 1151 
protein, except for the bottom row, which covers 9 amino acids and includes the last residue at 1152 
position 264. The panels on the left correspond to plasma samples collected at week 2 post 1153 
infection (PI). The panels on the right correspond to plasma samples collected at week 3 PI, or 1154 
week 4 PI in the case of r08046. Data from r08046, r05007, r08062, and r08047 are shown in A, 1155 
B, C, and D, respectively.  1156 
 1157 
Figure 10. env sequence diversity in acute phase plasma from four Group 2 controllers. 1158 
Heat maps illustrating the levels of sequence diversity at each codon in the env open reading 1159 
frame. The range of amino acids covered by each row is indicated on the right-hand side of the 1160 
figure only as a reference because both synonymous and non-synonymous mutations are 1161 
considered in these heat maps. When applicable, the frequency and location of amino acid 1162 
substitutions are described in the text of the manuscript and in Figure 11. The codon 1163 
corresponding to the first amino acid in Env is located in the top left corner of each grid. Each 1164 
row spans 30 amino acids of the Env protein, except for the bottom row, which covers 9 amino 1165 
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acids and includes the last residue at position 879. The panels on the left correspond to plasma 1166 
samples collected at week 2 post infection (PI). The panels on the right correspond to plasma 1167 
samples collected at week 3 PI, or week 4 PI in the case of r08046. Data from r08046, r05007, 1168 
r08062, and r08047 are shown in A, B, C, and D, respectively.  1169 
 1170 
Figure 11. Summary of amino acid substitutions in Env present at ≥10% frequencies in 1171 
acute phase samples from four Group 2 controllers. Each substitution is enclosed by a 1172 
square and its details are listed in a text box outside the Env main sequence. The details 1173 
provided for each amino acid substitution include the animal ID, time point post infection, 1174 
position in the Env protein, and the frequency of sequence reads displaying the wild-type 1175 
(boldface type) and mutant residues. As a reference, several topological features of the SIV Env 1176 
protein are shown in the figure, including the five variable loops (V) in gp120, the gp120/gp41 1177 
cleavage site, the membrane spanning domain and highly immunogenic region of gp41. The 1178 
location of the Mamu-B*17-restricted Env FW9 epitope is also indicated in the carboxyl terminus 1179 
of gp41.  1180 
 1181 
Figure 12. Association between titers of vaccine-induced gp140-binding Abs at the time 1182 
of the 1st SIV challenge and nadir viral loads in Group 2. This is a graphical representation 1183 
of the comparison between the log10 endpoint titers of vaccine-induced gp140-binding 1184 
antibodies at the time of the first IR SIV challenge and nadir viral loads in Group 2 listed in Table 1185 
3. The symbol for macaque r09062 (open black square) is masked by the symbol of r05007 1186 
(filled black square) because both animals had the same titer of gp140-binding antibodies 1187 
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(25,600) and nadir VL (15 vRNA copies/mL of plasma). The Bonferroni-corrected P value is 1188 
shown in the figure. Each symbol corresponds to one Group 2 vaccinee.  1189 
 1190 
  1191 
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Table 1. Serum neutralization of SIVmac239 in Group 2* 1192 
 1193 
Animal ID Day of 1st SIV challenge 
Week 6 
PI 
r08046 <20 <20 
r05007 <20 <20 
r08062 <20 <20 
r08047 <20 <20 
r08041 <20 <20 
r09062 <20 <20 
r04116 <20 <20 
rh1982 <20 <20 
 1194 
*Because none of the samples resulted in a 50% reduction in SIV infection in vitro at the lowest 1195 
reciprocal serum dilution (1:20), the 50% inhibitory dose for each animal is shown as <20. 1196 
  1197 
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Table 2. Percentage of viral sequences encoding intact Mamu-B*17-restricted CD8+ T-cell 1198 
epitopes in acute phase samples from four Group 2 controllers. 1199 
 1200 
 
Week 2 PI 
 
Week 3 or 4 PI 
Animal 
ID 
Vif 
HW8 
Nef 
IW9 
Nef 
MW9 
Env 
FW9  
Vif 
HW8 
Nef 
IW9 
Nef 
MW9 
Env 
FW9 
r08046* 100% 99.7% 100% 99.7% 
 
100% 100% 100% 96.6% 
r05007 100% 100% 100% 100% 
 
100% 100% 98.3% 98.2% 
r08062 100% 99.4% 99.3% 99.8% 
 
100% 99.7% 99.5% 94.9% 
r08047 N.A. N.A. N.A. N.A. 
 
100% 100% 100% 100% 
 1201 
N.A., not available. *No week 3 PI plasma was available from r08046 so the sample collected at 1202 
week 4 PI was used instead. 1203 
 1204 
  1205 
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Table 3. Correlations between immunological variables measured in vaccinees in Groups 1206 
1 and 2 and their respective nadir VLs. 1207 
 1208 
Immunological 
variable 
Groups 
included 
in the 
analysis 
Time 
point 
Correlation 
coefficient 
(r) 
Unadjusted 
P-value 
Bonferroni-
corrected 
P-value 
Total frequency of 
SIV-specific CD8+ T-
cell responses 
1 and 2 
Time of 
1st SIV 
challenge 
–0.18 0.53 1.0 
Total frequency of 
SIV-specific CD4+ T-
cell responses 
1 and 2 
Time of 
1st SIV 
challenge 
–0.25 0.37 1.0 
Total frequency of 
Mamu-B*17 
tetramer+ CD8+ T-
cells 
1 and 2 
Time of 
1st SIV 
challenge 
–0.19 0.5 1.0 
Total frequency of 
Mamu-B*17 
tetramer+ CD8+ T-
cells 
1 and 2 
Week 2.4 
PI 
0.4 0.14 1.0 
Area under the curve 
values for ADCC 
2 
Time of 
1st SIV 
–0.49 0.22 1.0 
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 1209 
 1210 
  1211 
challenge 
Area under the curve 
values for ADCC 
2 
Week 2.4 
PI 
0.14 0.75 1.0 
Titer of gp140-
binding Abs 
2 
Time of 
1st SIV 
challenge 
–0.85 0.008 0.06 
Titer of gp140-
binding Abs 
2 
Week 2.4 
PI 
0.28 0.51 1.0 
 o
n
 January 16, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 59 
Table 4. Animal characteristics. 1212 
 1213 
Group 
Animal 
ID 
Age (years) at 
beginning of study 
Sex MHC class I 
1 r04105* 8.6 F Mamu-B*17 
1 r03139 9.6 F Mamu-B*17 
1 r08022 4.8 F Mamu-B*17 
1 r09090 3.6 M Mamu-B*17 
1 r07012 5.6 F Mamu-B*17 
1 r08034 4.8 M Mamu-B*17 
1 r09001 4.3 M Mamu-B*17 
1 r09022 4 M Mamu-B*17 
2 r08046 4.6 M Mamu-B*17 
2 r05007 8.2 F Mamu-B*17 
2 r08062 4.4 M Mamu-B*17 
2 r08047 4.6 M Mamu-A*02, -B*17 
2 r08041 4.7 F Mamu-B*17 
2 r09062 3.8 F Mamu-A*02, -B*17 
2 r04116 8.6 F Mamu-B*17 
2 rh1982 15 F Mamu-B*17 
3 r08051 4.6 M Mamu-B*17 
3 r04053 8.9 F Mamu-B*17 
3 r97081 15.6 F Mamu-B*17 
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 60 
3 r09073 3.8 M Mamu-B*17 
3 r10018 3.1 M Mamu-A*02, -B*17 
3 r09083 3.7 F Mamu-B*17 
3 r98038 14.9 M Mamu-B*17 
3 r09039 3.9 M Mamu-B*17 
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